|
|
|
¾ÆÆ®·ÎÇɰú ½ºÅÚ¸®½ºÆ® º´Çà ½Ã ±Ù½Ã ¾ïÁ¦ È¿°ú È®ÀÎ |
½Ì°¡Æ÷¸£ ±¹¸³¾È¼¾ÅÍ ¿¬±¸Áø |
|
|
±Û·Î¹ú ¾È°æ·»Áî Àü¹®±â¾÷ ¿¡½Ç·ÎÄÚ¸®¾Æ°¡ ÃÖ±Ù ½Ì°¡Æ÷¸£ ±¹¸³¾È¼¾ÅÍ(Singapore National Eye Centre)¿¡¼ ¹ßÇ¥ÇÑ ¿¬±¸ °á°ú¸¦ ÀοëÇϸç, ¾ÆÆ®·ÎÇÉ ¾È¾àÀ» »ç¿ëÇÏ´Â ¾î¸°ÀÌ¿¡°Ô ±Ù½Ã ÁøÇà ¾ïÁ¦ ¾È°æ·»Áî ‘¿¡½Ç·Î ½ºÅÚ¸®½ºÆ®’°¡ º´Çà Ä¡·á·Î ÀûÇÕÇÒ ¼ö ÀÖ´Ù°í ¹àÇû´Ù[1].
½Ì°¡Æ÷¸£ ±¹¸³¾È¼¾ÅÍ ¿¬±¸ÁøÀº ¾Æ½Ã¾Æ Áö¿ª¿¡¼ ±ÞÁõÇϰí ÀÖ´Â ¼Ò¾Æ±Ù½ÃÀÇ È¿°úÀûÀÎ Ä¡·á¹ýÀ» ã°íÀÚ ¿¬±¸ÇßÀ¸¸ç, Àú³óµµ ¾ÆÆ®·ÎÇÉ Ä¡·á¸¦ ¹Þ°í ÀÖ´Â ¼Ò¾Æ±Ù½Ã ȯÀÚ°¡ ‘¿¡½Ç·Î ½ºÅÚ¸®½ºÆ®’ Âø¿ëÀ» º´ÇàÇßÀ» ¶§ ±Ù½Ã ÁøÇàÀÌ À¯ÀǹÌÇÏ°Ô °¨¼ÒÇß´Ù°í ÃÖ±Ù ¹ßÇ¥Çß´Ù[1].
À̹ø ¿¬±¸´Â Àú³óµµ ¾ÆÆ®·ÎÇÉ »ç¿ë¿¡µµ ±Ù½Ã°¡ Áö¼ÓÀûÀ¸·Î ÁøÇàµÈ ¸¸ 6¼¼¿¡¼ 11¼¼ »çÀÌÀÇ ¾î¸°ÀÌ 50¸íÀ» ´ë»óÀ¸·Î ÁøÇàµÆ´Ù. ´ë»óÀÚµéÀº 0.01% ³óµµ ¾ÆÆ®·ÎÇÉ ±×·ì(20¸í)°ú 0.025% ³óµµ ¾ÆÆ®·ÎÇÉ ±×·ì(30¸í)À¸·Î ³ª´µ¾î, ±âÁ¸ Ä¡·á¸¦ À¯ÁöÇÏ¸é¼ ‘¿¡½Ç·Î ½ºÅÚ¸®½ºÆ®’¸¦ ÇÔ²² Âø¿ëÇß´Ù.
‘¿¡½Ç·Î ½ºÅÚ¸®½ºÆ®’ Âø¿ë Àü 6°³¿ù µ¿¾È Æò±Õ ±Ù½Ã ÁøÇàÀº ¾à -0.60D, ¾ÈÃàÀå Áõ°¡´Â 0.24mm¿´´ø ¹Ý¸é, º´Çà Âø¿ë ÈÄ 12°³¿ù ½ÃÁ¡¿¡´Â ±Ù½Ã ÁøÇàÀÌ -0.07D, ¾ÈÃàÀå Áõ°¡´Â 0.13mm·Î ÇöÀúÈ÷ °¨¼ÒÇß´Ù. ¶ÇÇÑ Àüü ´ë»óÀÚÀÇ 22%¿¡¼´Â ¾È±¸ ±æÀ̰¡ ¿ÀÈ÷·Á ÁÙ¾îµå´Â ¿ø½Ã¼º ¾ÈÃàÀå À̵¿ Çö»óÀÌ °üÂûµÆ´Ù[1]. À̹ø °á°ú´Â ¾ÆÆ®·ÎÇÉ ¾È¾à°ú ‘¿¡½Ç·Î ½ºÅÚ¸®½ºÆ®’ º´Çà ½Ã ±Ù½Ã ÁøÇà ¾ïÁ¦ È¿°ú°¡ Áõ°¡ÇÒ ¼ö ÀÖÀ½À» ½Ã»çÇÑ´Ù. ´Ü, ¾ÆÆ®·ÎÇɰúÀÇ º´Çà Ä¡·á´Â ¾È°ú Àü¹®ÀÇ¿ÍÀÇ ÃæºÐÇÑ »ó´ãÀ» °ÅÃÄ °áÁ¤ÇÏ´Â °ÍÀÌ ±Ç°íµÈ´Ù.
Áö³ÇØ 10¿ù ±¹³» Ãâ½ÃÇÑ ‘¿¡½Ç·Î ½ºÅÚ¸®½ºÆ®’´Â °íµµÈµÈ ºñ±¸¸é ¸¶ÀÌÅ©·Î·»Áî(H.A.L.T, Highly Aspherical Lenslet Target) ±â¼úÀ» Àû¿ëÇØ ¸ÅÀÏ 12½Ã°£ Âø¿ë ½Ã ±Ù½Ã ÁøÇàÀ» 67% ¾ïÁ¦ÇÑ´Ù[2]. ·»Áî Ç¥¸é¿¡ 1021°³ÀÇ ¸¶ÀÌÅ©·Î·»Á 11°³ÀÇ ¸µ ÇüÅ·Π¹èÄ¡ÇØ ±Ù½Ã ÁøÇàÀ» ´ÊÃ߸鼵µ, ´ÜÃÊÁ¡ ¾È°æ·»Áî¿Í °°Àº ¼±¸íÇÑ ½Ã¾ß¸¦ Á¦°øÇÑ´Ù[3].
¿¡½Ç·ÎÄÚ¸®¾ÆÀÇ °¹ÎÁö ½ºÅÚ¸®½ºÆ® Á¦Ç° ´ã´ç Â÷ÀåÀº “À̹ø ¿¬±¸ °á°ú´Â ‘¿¡½Ç·Î ½ºÅÚ¸®½ºÆ®’ ¾È°æ·»Áî¿Í ¾ÆÆ®·ÎÇÉ ¾È¾àÀÇ º´Çà Ä¡·á°¡ ¾î¸°ÀÌ ±Ù½Ã °ü¸®¿¡ ±àÁ¤ÀûÀÎ °¡´É¼ºÀ» Á¦½ÃÇÑ´Ù´Â Á¡¿¡¼ Å« Àǹ̰¡ ÀÖ´Ù”¸ç “ÀÚ³àÀÇ ±Ù½Ã·Î °í¹ÎÇÏ´Â Çкθð¶ó¸é, ¾È°ú Àü¹®ÀÇ¿ÍÀÇ »ó´ãÀ» ÅëÇØ ¾ÆÆ®·ÎÇɰúÀÇ º´Çà Ä¡·á ¹æ¾ÈÀ» °í·ÁÇØ º¸±æ ±ÇÇÑ´Ù”°í ÀüÇß´Ù.
[1] Additive Effect of Highly Aspherical Lens let Target Spectacles to Children Inadequately Controlled by Atropine Monotherapy. Sim, Bryan Xiangrong et al. Ophthalmology Science, Volume 5, Issue 4, 100753
[2] Áß±¹ ¿øÀú¿ì¿¡¼ ¿¡½Ç·Î ½ºÅÚ¸®½ºÆ®¸¦ Âø¿ëÇÑ ±Ù½Ã ¾î¸°ÀÌ 54¸í°ú ¿¡½Ç·Î ·è¼ÒƼī ÀÚ»çÀÇ ´ÜÃÊÁ¡ ·»Á Âø¿ëÇÑ ±Ù½Ã ¾î¸°ÀÌ 50¸íÀ» ´ë»óÀ¸·Î ÇÑ 2³â°£ÀÇ ÀüÇâÀû, ´ëÁ¶±ºÀÌ ÀÖ´Â, ¹«ÀÛÀ§¹èÁ¤, ÀÌÁß¸Í°Ë ÀÓ»ó½ÃÇè °á°ú. 32¸íÀÇ ¾î¸°À̵éÀÌ ¿¬¼Ó 2³â µ¿¾È ¸ÅÀÏ ÃÖ¼Ò 12½Ã°£ ¿¡½Ç·Î ½ºÅÚ¸®½ºÆ®¸¦ Âø¿ë½Ã. Bao J, Huang Y, Li X, Yang A, Zhou F, Wu J, Wang C, Li Y, Lim EW, Spiegel DP, Drobe B, Chen, H. Spectacle lenses with aspherical lenslets for myopia control vs single-vision spectacle lenses: a randomized clinical trial. JAMA ophthalmology. 2022;140(5):472-8. doi:10.1001/jamaophthalmol.2022.0401
[3] Two-year prospective, controlled, randomized, double-masked clinical trial results on 54 myopic children wearing Stellest® lenses compared to 50 myopic children wearing single vision lenses. Results based on 32 children who declared wearing Stellest® lenses at least 12 hours per day every day. Bao, J. et al. (2021). One-year myopia control efficacy of spectacle lenses with aspherical lenslets. Br. J. Ophthalmol. doi:10.1136/bjophthalmol-2020-318367.
|
|
Àüü´º½º¸ñ·ÏÀ¸·Î |
|
|
|
|
|